UNSPSC 51332102: Nemonapride

This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q88T5P3444, chemically known as n-(2rs,3rs)-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide but generally known as nemonapride, which bears US NIH Compound Identifier 156333. European Medicines Agency schedules Nemonapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09191MIG.

UNSPSC 51332102 Nemonapride is a Commodity code representing pharmaceutical products, specifically nemonapride active pharmaceutical ingredients and formulations, though recent state and local procurement activity under this code shows significant misalignment between the code's nominal classification and actual purchasing patterns. The three most recent opportunities solicited under this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). The issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances, indicating fragmented demand across different levels of government. The work being solicited includes procurement of finished pharmaceutical products for community health initiatives, establishment of vendor capabilities for prescription fulfillment pathways, and sourcing of generic pharmaceuticals and over-the-counter items for state and local government facilities.

Recent activity concentrates in Florida, Texas, and Minnesota, with the most concrete opportunity being Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford. Texas HHS issued an RFI (HHS0017013) on April 3, 2026 to gather vendor information on direct-to-manufacturer prescription programs, signaling early-stage state interest in alternative pharmacy benefit delivery models. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and maintain compliance with cGMP and Drug Supply Chain Security Act standards. The code shows active state and local demand for pharmaceutical supply but lacks clear focus on nemonapride specifically; buyers are sourcing broadly across pharmaceutical categories and delivery pathways rather than seeking this ingredient or formulation in isolation.